Canada's Aurinia Pharmaceuticals Q1 revenue rises 24% on LUPKYNIS demand

Aurinia Pharmaceuticals

07/05/2026 13:10

Overview

Canada biopharma's Q1 revenue rose 24% yr/yr, driven by LUPKYNIS sales and collaboration gains

Q1 net income increased 48% yr/yr, with diluted EPS up 56%

Company repurchased 2.5 mln shares for $36.2 mln in Q1

Outlook

Aurinia reiterates 2026 total revenue guidance of $315 mln to $325 mln

Company maintains 2026 net product sales forecast at $305 mln to $315 mln

Aurinia says LUPKYNIS is emerging as standard-of-care for lupus nephritis

Result Drivers

LUPKYNIS SALES - Higher net product sales of LUPKYNIS drove revenue growth in Q1

COLLABORATION REVENUE - Increased license, collaboration and royalty revenue from Otsuka contributed to total revenue growth

Company press release: ID:nBw9Rh4Tba

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
$73.56 mln
Q1 Net Income
$34.36 mln
Q1 Operating Expenses
$36.28 mln
Q1 Operating Income
$41.42 mln
Q1 Pretax Profit
$43.93 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)